V2 Cloud sunsets August 10, 2026. Own TexAu on your machine.

Founder price $1,499 one-time — unlimited hours, no proxies, runs locally. Ends June 10, 2026. Pre-order V2 Desktop →

Back to profiles
MBX Biosciences logo

MBX Biosciences

MBX Biosciences has raised $216 million across three funding rounds, supported by leading biotech investors including Frazier Healthcare Partners, Orbimed, Wellington, RA Capital Management, Deep Track Capital, and others. The company’s funding history includes a Series A of $34.6M, Series B of $115M, and a Series C of $63.5M, backing its mission to develop precision therapies for rare endocrine disorders. With strong investor confidence and a focused drug development pipeline, MBX Biosciences continues to expand clinical programs and strengthen its leadership in endocrine therapeutics.